Arun Swaminathan Acquires 5,000 Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) CEO Arun Swaminathan purchased 5,000 shares of Coya Therapeutics stock in a transaction on Monday, November 11th. The stock was bought at an average price of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the acquisition, the chief executive officer now owns 5,000 shares in the company, valued at $36,700. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Coya Therapeutics Trading Down 1.1 %

COYA traded down $0.08 during midday trading on Tuesday, hitting $7.25. 75,269 shares of the company traded hands, compared to its average volume of 71,656. The company has a market capitalization of $121.13 million, a price-to-earnings ratio of -11.28 and a beta of 0.46. Coya Therapeutics, Inc. has a 52-week low of $4.75 and a 52-week high of $10.69. The business has a 50 day simple moving average of $7.05 and a two-hundred day simple moving average of $7.02.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.15. Equities research analysts anticipate that Coya Therapeutics, Inc. will post -1.27 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Monday. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, November 7th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Gilbert & Cook Inc. purchased a new position in shares of Coya Therapeutics in the 2nd quarter valued at about $61,000. Renaissance Technologies LLC acquired a new stake in shares of Coya Therapeutics during the 2nd quarter worth about $101,000. GHP Investment Advisors Inc. acquired a new stake in shares of Coya Therapeutics during the 3rd quarter worth about $169,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after acquiring an additional 750,338 shares during the period. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.